---
title: "RIGL: Rigel licensed VEPPANU from Arvinas/Pfizer for $70M upfront plus milestones and royalties"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294865550.md"
description: "Rigel secured an exclusive global license for VEPPANU (Vepdegestrant) from Arvinas and Pfizer, paying $70M upfront plus milestones and royalties, and amended its credit facility to permit the transaction. The agreement grants Rigel full commercial rights and responsibilities, with robust compliance and termination provisions, and positions VEPPANU for commercial launch in August 2026.Original document: Rigel Pharmaceuticals, Inc. [RIGL] SEC 10-Q Quarterly Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-04T20:17:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294865550.md)
  - [en](https://longbridge.com/en/news/294865550.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294865550.md)
---

# RIGL: Rigel licensed VEPPANU from Arvinas/Pfizer for $70M upfront plus milestones and royalties

Rigel secured an exclusive global license for VEPPANU (Vepdegestrant) from Arvinas and Pfizer, paying $70M upfront plus milestones and royalties, and amended its credit facility to permit the transaction. The agreement grants Rigel full commercial rights and responsibilities, with robust compliance and termination provisions, and positions VEPPANU for commercial launch in August 2026.

Original document: Rigel Pharmaceuticals, Inc. \[RIGL\] SEC 10-Q Quarterly Report — Aug. 4 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RIGL.US](https://longbridge.com/en/quote/RIGL.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ARVN.US](https://longbridge.com/en/quote/ARVN.US.md)

## Related News & Research

- [Pfizer repels Covid-19 sales tumble to raise 2026 guidance](https://longbridge.com/en/news/294878492.md)
- [Pfizer extends rally to seventh straight session](https://longbridge.com/en/news/295454569.md)
- [Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan](https://longbridge.com/en/news/294880787.md)
- [Pfizer says Q2 2026 results beat expectations on non-COVID brand growth and cost discipline](https://longbridge.com/en/news/294808934.md)
- [BUZZ-Street View: Growth drugs lift Pfizer outlook, but execution remains key](https://longbridge.com/en/news/294968791.md)